A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
By M. Cappellini, A. Cohen, A. Piga, M. Bejaoui, S. Perrotta, L. Ağaoğlu, Y. Aydinok, A. Kattamis, Y. Kilinç, J. Porter and 18 more. Blood, 2006
687 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Pediatrics, Perinatology and Child Health
View Paper: https://www.semanticscholar.org/paper/303bceef0b1869dfadb4db2b2f90b92c24286057
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- J. Kato
- Y. Torimoto
- T. Ohtake
- R. Galanello
- K. Ikuta
- Y. Kohgo
- R. Origa
Citations in the corpus
- Body iron metabolism and pathophysiology of iron overload (2008, background): “The clinical studies concerning the relationship between blood transfusion and SF have been conducted mainly in the Europe and US, showing that there is a clearcut positive correlation between the amount of chronic blood transfusion and the elevation of SF in patients with b-thalassemia [26, 27].”
- Beta-thalassemia (2010, background): “Deferasirox (DFX) is a once-daily, orally administered iron chelator that a large program of clinical trials has shown to be effective in adults and children [64,65].”